MEDICAL DEVICES

PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology

The open-label, multicenter, Phase IIa study was designed to evaluate [...]

By |2022-02-18T17:42:31+00:00February 18, 2022|3rd Party Medical Device Industry News|Comments Off on PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology
Go to Top